CPT code 0289U designates a proprietary laboratory test — the MindX Blood Test™ – Memory/Alzheimer’s from MindX Sciences™ Inc. — that uses next-generation sequencing (NGS) of RNA to evaluate expression of 24 genes and an algorithmic analysis to produce a predictive risk score for Alzheimer’s disease and other memory conditions. As a PLA code, 0289U is limited to a single manufacturer's lab test and signals a specific clinical diagnostic service in the growing field of molecular neurology diagnostics.

Key national payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Coverage and payment policies for PLA codes like 0289U are important because they affect patient access to proprietary diagnostic tools, influence laboratory adoption, and shape utilization of advanced genomic assays in neurology and memory care pathways.

Readers will find benchmarks and context on how 0289U fits into laboratory service lines, an overview of likely sites of service and clinical use, and a summary of payer coverage considerations and common billing practices. The publication also outlines implications for coding workflows and documentation when reporting a PLA diagnostic assay nationally.